Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

References

• AmoakuWBlakeneySFreemanMAction on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient careEye201226Suppl 1S2S2122302094
   PubMed Web of Science ®Google Scholar
• TownsendDReevesBCTaylorJHealth professionals’ and service users’ perspectives of shared care for monitoring wet age-related macular degeneration: a qualitative study alongside the ECHoES trialBMJ Open201554e007400
   Web of Science ®Google Scholar
• OwenCGJarrarZWormaldRCookDGFletcherAERudnickaARThe estimated prevalence and incidence of late stage age related macular degeneration in the UKBr J Ophthalmol201296575275622329913
   PubMed Web of Science ®Google Scholar
• NICERanibizumab and pegaptanib for the treatment of age-related macular degeneration2012 Available from: https://www.nice.org.uk/guidance/ta155Accessed November 22, 2017
   Google Scholar
• HatzKPrünteCTreat and Extend vs pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 month studyActa Ophthalmol2017951e67e7227009503
   PubMed Web of Science ®Google Scholar
• MehtaHTufailADaienVReal-world outcomes in patients with neovascular age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitorsProg Retin Eye Res20186512714629305324
   PubMed Web of Science ®Google Scholar
• Writing Committee for the UK Age-Related Macular Degeneration EMR Users GroupThe neovascular age-related macular degeneration database: multicenter study of 92976 ranibizumab injections: report 1: visual acuityOphthalmology201412151092110124461586
   PubMed Web of Science ®Google Scholar
• ChavanRPanneerselvamSAdhanaPNarendranNYangYBilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degenerationClin Ophthalmol2014871772324748766
   PubMedGoogle Scholar
• Lucentis (ranibizumab)Summary of Product Characteristics2011 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdfAccessed November 22, 2017
   Google Scholar
• VardarinosAGuptaNJanjuaRIronAEmpeslidisTTsaousisKT24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life settingBMC Ophthalmol20171715828449645
   PubMed Web of Science ®Google Scholar
• WykoffCCCroftDEBrownDMProspective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year resultsOphthalmology2015122122514252226391465
   PubMed Web of Science ®Google Scholar
• WykoffCCOuWCCroftDENeovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trialBr J Ophthalmol2018102446046428779006
   PubMed Web of Science ®Google Scholar
• RufaiSRAlmuhtasebHPaulRMA systematic review to assess the ‘treat-and-extend’ dosing regimen for neovascular age-related macular degeneration using ranibizumabEye20173191337134428475181
   PubMed Web of Science ®Google Scholar
• KimLNMehtaHBarthelmesDNguyenVGilliesMCMetaanalysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degenerationRetina20163681418143127388744
   PubMed Web of Science ®Google Scholar
• YangYDowneyLMehtaHResource use and real-world outcomes for ranibizumab treat and extend for neovascular age-related macular degeneration in the UK: interim results from TERRAOphthalmol Ther20176117518628508241
   PubMed Web of Science ®Google Scholar
• GuptaOPShienbaumGPatelAHFecarottaCKaiserRSRegilloCDA treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impactOphthalmology2010117112134214020591490
   PubMed Web of Science ®Google Scholar
• HolzFGAmoakuWDonateJSafety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN studyOphthalmology2011118466367121459217
   PubMed Web of Science ®Google Scholar
• AmoakuWMChakravarthyUGaleRDefining response to anti-VEGF therapies in neovascular AMDEye201529672173125882328
   PubMed Web of Science ®Google Scholar
• KvannliLKrohnJSwitching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degenerationActa Ophthalmol201795767868228139082
   PubMed Web of Science ®Google Scholar
• LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091485814358
   Web of Science ®Google Scholar
• EngelbertMZweifelSAFreundKB“Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferationRetina200929101424143119898180
   PubMed Web of Science ®Google Scholar
• GilliesMHunyorAArnoldJComparison of ranibizumab and aflibercept in patients with neovascular age-related macular degeneration treated following a ‘treat and extend’ protocol: efficacy variables from the 12-month interim analysis of the RIVAL studyAbstract presented at EURETINA2017September 7–10, 2017Barcelona, Spain
   Google Scholar
• EssexRWNguyenVWaltonRTreatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degenerationOphthalmology2016123112393240027554034
   PubMed Web of Science ®Google Scholar
• AdreanSDChailiSRamkumarHPirouzAGrantSConsistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocolOphthalmology201812571047105329439828
   PubMed Web of Science ®Google Scholar
• CATT Research GroupMartinDFMaguireMGRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• IVAN Study InvestigatorsChakravarthyUHardingSPRanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology201211971399141122578446
   PubMed Web of Science ®Google Scholar
• BarthelmesDNguyenVDaienVTwo year outcomes of “treat and extend” intravitreal therapy using aflibercept preferentially for neovascular age-related macular degenerationRetina2018381202828145976
   PubMed Web of Science ®Google Scholar
• RodriguesIASprinkhuizenSMBarthelmesDDefining a minimum set of standardized patient-centered outcome measures for macular degenerationAm J Ophthalmol201616811227131774
   PubMed Web of Science ®Google Scholar
• NICEAge-related macular degeneration (NG82)2018 Available from: https://www.nice.org.uk/guidance/ng82Accessed February 2018
   Google Scholar
• AbdelfattahNSAl-SheikhMPitettaSMacular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trialOphthalmology2017124221522327863845
   PubMed Web of Science ®Google Scholar
• HykinPChakravarthyULoteryAMckibbinMNapierJSivaprasadSA retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UKClin Ophthalmol201610879626834453
   PubMedGoogle Scholar
• SilvaRBertaALarsenMTreat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND studyOphthalmology20181251576528893454
   PubMed Web of Science ®Google Scholar
• GangnonRELeeKEKleinBEIyengarSKSivakumaranTAKleinRSeverity of age-related macular degeneration in 1 eye and the incidence and progression of age-related macular degeneration in the fellow eye: the Beaver Dam Eye StudyJAMA Ophthalmol2015133212513225340497
   PubMed Web of Science ®Google Scholar
• ToalsterNRussellMNgPA 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degenerationRetina20133371351135823538578
   PubMed Web of Science ®Google Scholar
• RayessNHoustonSKGuptaOPHoACRegilloCDTreatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimenAm J Ophthalmol201515913825217859
   PubMed Web of Science ®Google Scholar
• OubrahamHCohenSYSamimiSInject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degenerationRetina2011311263020890246
   PubMed Web of Science ®Google Scholar
• HatzKPrünteCChanging from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degenerationBr J Ophthalmol2016100101341134526755642
   PubMed Web of Science ®Google Scholar
• EngelbertMZweifelSAFreundKBLong-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified “treat and extend” dosing regimen of intravitreal antivascular endothelial growth factor therapyRetina20103091368137520517175
   PubMed Web of Science ®Google Scholar
• BergKHadzalicEGjertsenIRanibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend protocol: two-year resultsOphthalmology20161231515926477842
   PubMed Web of Science ®Google Scholar
• BergKPedersenTRSandvikLBragadóttirRComparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocolOphthalmology2015122114615225227499
   PubMed Web of Science ®Google Scholar
• ArnoldJJCampainABarthelmesDTwo-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degenerationOphthalmology201512261212121925846847
   PubMed Web of Science ®Google Scholar
• AbediFWickremasingheSIslamAFInglisKMGuymerRHAnti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 yearsRetina20143481531153824637667
   PubMed Web of Science ®Google Scholar
• CalvoPWangYFerrerasALamWCDevenyiRBrentMHTreat and extend versus treat and observe regimens in wet age-related macular degeneration patients treated with ranibizumab: 3-year surveillance periodJ Clin Exp Ophthalmol20145324
   Google Scholar
• ChenYNPowellAMMaoASheidowTGRetrospective review of lucentis ‘treat and extend’ patterns and outcomes in age-related macular degenerationRetina201636227227826200511
   PubMed Web of Science ®Google Scholar
• MrejenSJungJJChenCLong-term visual outcomes for a treat and extend anti-vascular endothelial growth factor regimen in eyes with neovascular age-related macular degenerationJ Clin Med2015471380140226239682
   PubMed Web of Science ®Google Scholar
• GilliesMCCampainABarthelmesDLong-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational studyOphthalmology201512291837184526096346
   PubMed Web of Science ®Google Scholar